权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Core 1: Planning and Evaluation

核心1：规划与评估

基本信息

批准号：
10762163
负责人：
David K Ann
金额：
$ 12.42万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10762163
关键词：
Award California City of Hope Comprehensive Cancer Center Clinical Trials Collaborations Communities Comprehensive Cancer Center Contractor Databases Education Educational process of instructing Educational workshop Effectiveness Equity Evaluation Feedback Funding Future Goals Grant Individual Joints Knowledge Leadership Measures Mentors Mentorship Modeling Monitor Outcome Measure Performance Pilot Projects Play Process Program Evaluation Progress Reports Publications Recommendation Reporting Research Research Personnel Resources Structure Surveys Therapeutic Training Training Programs Training and Education Translational Research United States National Institutes of Health Universities Work anticancer research cancer health disparity career career development drug development equity, diversity, and inclusion health disparity improved insight meetings outreach programs success webinar

项目摘要

The goals of the Planning and Evaluation Core (PEC) are to monitor, evaluate, and assess the progress of our U54 Partnerships in meeting its milestones, objectives, and goals. The Core supports our University of California, Riverside (UCR) – City of Hope Comprehensive Cancer Center (CoHCCC) U54 Partnership’s goals of capacity- building, education, and training. Together in this U54, UCR and CoHCCC aim to develop the collaborations, translational resources, and training programs to enhance diversity in cancer research and achieve equity in drug development - throughout the entire drug development pipeline. To achieve our PEC’s goals we are guided by four boards – the Internal Advisory Board (IAB), External Advisory Board (EAB), Community Advisory Board (CAB), and Diversity, Equity, and Inclusion Board (DEI). Our IAB and EAB have served a key role in guiding our P20 planning grant; in our proposed U54 these two boards will be joined by our newly created CAB and DEI. The inclusion of these two new boards underscores our U54’s commitment to 1) serving the diverse individuals that live in our Southern California communities and 2) to mentor and train a diverse early-stage investigators who are committed to eliminating our current disparities in cancer therapeutics, drug development, and access to clinical trials. Through the activities and oversight of the PEC, our four advisory boards will 1) conduct evaluation, tracking, and reporting of the progress of projects and cores and 2) provide focused feedback to program U54 leadership and investigators. As in our P20 planning grant, the U54 PEC will work with the IAB to provide a structured and rigorous review process to select new Full and Pilot projects as well as Mini-Pilots for the Capacity Core. The PEC will assess all components of our U54 partnership. The PEC will assure that the 1) Research and Evaluation Core training and education programs are effective in providing education and building capacity, 2) Outreach Core works with investigators to be inclusive of the communities we serve, and 3) Capacity Core identifies provides early-stage investigators (ESI) with mentorship in target identification, drug development, and clinical trials. We anticipate that together our Cores will play a key role in developing future U54 projects that build UCR’s capacity in drug development and clinical trials.

规划和评价核心(PEC)的目标是监测、评价和评估我们的 U54在实现其里程碑、目标和目标方面的伙伴关系。核心支持我们的加州大学，河滨(UCR)-希望之城综合癌症中心(CoHCCC)U54合作伙伴的能力目标- 建设、教育和培训。在U54中，UCR和CoHCCC共同致力于发展合作，翻译资源和培训计划，以增强癌症研究的多样性和实现公平药物开发-贯穿整个药物开发流水线。为了实现PEC的目标，我们在指导下由四个委员会--内部咨询委员会(IAB)、外部咨询委员会(EAB)、社区咨询委员会 (CAB)和多样性、公平和包容性委员会(DEI)。我们的IAB和EAB在指导我们的 P20规划拨款；在我们提议的U54中，这两个董事会将由我们新创建的CAB和Dei加入。这两个新董事会的加入突显了我们U54的S承诺：1)服务于不同的个人他们生活在我们的南加州社区，2)指导和培训多样化的早期调查人员他们致力于消除我们目前在癌症治疗、药物开发和获取方面的差距到临床试验。通过PEC的活动和监督，我们的四个咨询委员会将1) 评价、跟踪和报告项目和核心的进展情况；2)提供有针对性的反馈计划U54领导层和调查人员。与我们的P20规划拨款一样，U54 PEC将与IAB合作提供结构化和严格的审查流程，以选择新的全面和试点项目以及迷你试点项目能力核心。PEC将评估我们U54伙伴关系的所有组成部分。PEC将保证 1)研究和评估核心培训和教育方案在提供教育和能力建设，2)外联核心与调查人员合作，以涵盖我们所服务的社区，以及3) 能力核心识别为早期调查人员(ESI)提供靶标识别、药物方面的指导开发和临床试验。我们预计，我们的核心将在未来的发展中发挥关键作用 U54个项目，建设UCR在药物开发和临床试验方面的能力。